NYSE: EW · Medical Devices

Edwards Lifesciences (EW) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Edwards Lifesciences (EW) at $88.12 a share. The stock last closed at $107.11, which puts the model's fair value 17.7% below the price. On the model's bands that reads as Overvalued.

Revalued . Price is the close of 16 Nov 2026. Edwards Lifesciences Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$88.12midpoint of 2,000 simulations
Last close$107.11NYSE: EW
Gap to fair value-17.7%fair value against price
Model verdictOvervaluedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $83.19 to $88.12 (+5.9%). The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move.

What the model makes of itThe price of $107.11 is 17.7% above it: Overvalued, on a high evidence grade.

What's nextNext report on 9 Feb 2027. Options prices imply a move of about 8% either way over the next month. On the model's Quality Momentum list since 10 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give EW?

The calibrated range for EW over 63 trading days is $97.79 to $117.86. It sits around the last close, and its width comes from the volatility that EW's own options imply (28% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $75.20 to $102.30. In 14% of the simulations the fair value came out above the price the model ran on.

$62.47$125.11
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $88.12. Dashed line: the last close, $107.11.

Faircurve Insights · 14 Nov 2026

Edwards Lifesciences Corporation is a global medical technology firm. It specialises in products for structural heart conditions, alongside critical care and surgical patient monitoring.

Faircurve's model put the fair value at $88.12 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $83.19, so the fair value moved +5.9%. The model gives the reason in its own words: "The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move." The calibrated range over 63 trading days is $97.79 to $117.86, built around the price from the volatility the stock's own options imply. The range is calibrated weekly against realised prices, using 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. It does not say whether the fair value is right.

The model's quality score for Edwards is 61 out of 100, a composite of six factors scored against comparable companies. The balance sheet scores 100, with net debt to EBITDA at -1.50x against a peer median of 0.60x. Earnings quality scores 79, with FCF to net income at 1.39x against a peer median of 1.13x. Stability scores 10, with EBITDA margin downside volatility at 3.6 pts over five years against a peer median of 1.6 pts. The comparable companies are Boston Scientific, GE HealthCare, Stryker, DexCom, Medtronic, Abbott and Zimmer Biomet.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does EW report earnings, and how has the stock reacted?

Edwards Lifesciences's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 6.4% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. EW's 30 day implied volatility works out to about 8.0% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across EW's last 8 reports, ignoring direction, was 3.3%.

0%5%10%8.7%6.4%23 Apr '258.3%4.0%24 Jul '258.0%0.3%30 Oct '257.5%3.3%10 Feb '268.7%3.2%23 Apr '268.8%2.1%23 Jul '269.6%0.3%29 Oct '267.2%5.9%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in EW

0%5%10%15%20%4 Nov '26 report29 Oct '26 report23 Jul '26 report23 Apr '26 report10 Feb '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 7% on 14 Nov 2025, reached 14% on 30 Oct 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does EW score on business quality?

Edwards Lifesciences's overall quality score is 61 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.5013.7%ROIC15.5%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).791.39xFCF / net income1.13x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.7511.5%Revenue growth, trailing10.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.401.2%Net buybacks / market value1.6%
Balance sheetNet debt to EBITDA and interest coverage.100-1.50xNet debt / EBITDA0.60x
StabilityDownside volatility of the EBITDA margin over the last five years.103.6 ptsEBITDA margin downside volatility, 5y1.6 pts

How does EW compare with similar companies?

The companies in medical devices closest to Edwards Lifesciences in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
BSX Boston Scientific Corporation$43.69$52.05+19.1%Undervalued
GEHC GE HealthCare Technologies Inc.$82.96$90.14+8.7%Fairly valued
SYK Stryker Corporation$310.72$275.49-11.3%Fairly valued
DXCM DexCom, Inc.$81.61$73.84-9.5%Fairly valued
MDT Medtronic Plc$102.88$100.47-2.3%Fairly valued
ABT Abbott Laboratories$107.45$106.73-0.7%Fairly valued
ZBH Zimmer Biomet Holdings, Inc.$101.41$120.99+19.3%Undervalued
GKOS Glaukos Corporation$244.88$228.07-6.9%Data under review

What the comparable companies' multiples alone would give for EW, the peer-implied price, is $61.72 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

Edwards Lifesciences at a glance

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring.

Market value
$61.6B
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$7.4B
Consensus revenue growth, next fiscal year
+12.3%
Analysts with estimates
17
Beta to the US market
0.47
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. EW was not among them.

How the fair value is worked out: the model prices Edwards Lifesciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for EW was $83.19. As of 14 Nov 2026 it is $88.12, a change of +5.9%. The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Edwards Lifesciences's valuation

Is Edwards Lifesciences stock undervalued or overvalued?

On Faircurve's model, EW reads as Overvalued as of 14 Nov 2026. The model's fair value is $88.12 a share against a last close of $107.11, a gap of -17.7%.

What is EW's fair value?

$88.12 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $75.20 to $102.30.

What price range does the model give EW?

$97.79 to $117.86 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Edwards Lifesciences report earnings next?

The next report is scheduled for 9 Feb 2027. Companies can move their dates.

How much has EW moved on past earnings reports?

Across its last 8 reports the median two session move was 3.3%, ignoring direction. The largest was +6.4% around the report of 23 Apr 2025.

How confident is the model in this valuation?

The model's evidence grade for EW is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on EW

The model has an idea open on EW under Quality Momentum since 10 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on EW with their outcomes. A free account is enough.

Keep reading